TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10072664

Group type: EXPERIMENTAL
Intervention: Risperidone addition to neuroleptic treatment
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Mosapramine addition to neuroleptic treatment
Number of subjects: 10
Study: 7488404

Group type: EXPERIMENTAL
Intervention: Halsted mastectomy
Number of subjects: 1973

Group type: EXPERIMENTAL
Intervention: Quadrantectomy plus radiotherapy
Number of subjects: 1973

Group type: EXPERIMENTAL
Intervention: Lumpectomy plus radiotherapy
Number of subjects: 1973

Group type: EXPERIMENTAL
Intervention: Quadrantectomy without radiotherapy
Number of subjects: 1973

Group type: COMPARATOR
Intervention: Halsted mastectomy, Quadrantectomy plus radiotherapy, Lumpectomy plus radiotherapy, Quadrantectomy without radiotherapy
Number of subjects: 1973
Study: 1790543

Group type: EXPERIMENTAL
Intervention: Topilene (generic formulation) cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diprolene (innovator formulation) cream
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topilene (generic formulation) ointment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diprolene (innovator formulation) ointment
Number of subjects: 0
Study: 6264507

Group type: EXPERIMENTAL
Intervention: 0.243% sodium fluoride-silica abrasive dentifrice
Number of subjects: 1824

Group type: COMPARATOR
Intervention: 0.4% stannous fluoride-calcium pyrophosphate abrasive dentifrice
Number of subjects: 1824
Study: 31475494

Group type: EXPERIMENTAL
Intervention: TEAS at Zusanli (ST36) and Sanyinjiao (SP6) starting 30 min before surgery to the end of surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group received TEAS at the same acupoints with minimum current intensity
Number of subjects: 40
Study: 28495411

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) applied intraorally and extraorally with a 660-nm and 810-nm laser, respectively, at 200 mW for 10 seconds, 2 J, 1.5 J/cm2 and 7 J/cm2, repeated 2 times per week for 3 weeks.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control side received laser simulation instead of actual laser therapy.
Number of subjects: 16
Study: 26159384

Group type: COMPARATOR
Intervention: 35% hydrogen peroxide (single session‐45 min)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: 5% potassium nitrate dentifrice and in‐office experimental pastes (D4 and D5)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: D1‐experimental dentifrice containing bioactive glass‐ceramic
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: D4-experimental bioactive glass‐ceramic and D5-experimental Bioglass type 45S5
Number of subjects: 140
Study: 23377193

Group type: EXPERIMENTAL
Intervention: Intensive glycemic control
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Thiazolidinedione (TZD) use
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: A1C levels
Number of subjects: 73
Study: 21748445

Group type: EXPERIMENTAL
Intervention: Melatonin administration (group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No melatonin administration (group B)
Number of subjects: 60
Study: 19487639

Group type: EXPERIMENTAL
Intervention: Weekly incontinence
Number of subjects: 2994

Group type: EXPERIMENTAL
Intervention: Non-Hispanic whites
Number of subjects: 2994

Group type: EXPERIMENTAL
Intervention: African Americans
Number of subjects: 2994

Group type: EXPERIMENTAL
Intervention: Asians
Number of subjects: 2994

Group type: EXPERIMENTAL
Intervention: BMI > or = 35 kg/m(2)
Number of subjects: 2994

Group type: EXPERIMENTAL
Intervention: Prior hysterectomy
Number of subjects: 2994

Group type: EXPERIMENTAL
Intervention: Urinary tract infection in the prior year
Number of subjects: 2994
Study: 16231342

Group type: EXPERIMENTAL
Intervention: Mirror Exposure (ME) therapy
Number of subjects: 45

Group type: COMPARATOR
Intervention: Nondirective (ND) therapy
Number of subjects: 45
Study: 15317832

Group type: EXPERIMENTAL
Intervention: Cilomilast
Number of subjects: 0

Group type: COMPARATOR
Intervention: Theophylline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cilomilast in smokers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cilomilast in nonsmokers
Number of subjects: 0
Study: 12152675

Group type: EXPERIMENTAL
Intervention: Atorvastatin, 20 mg/day
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 9828991

Group type: EXPERIMENTAL
Intervention: Daily Living Programme (DLP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DLP for 20 months followed by standard care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care throughout
Number of subjects: 0
Study: 7714303

Group type: EXPERIMENTAL
Intervention: Moclobemide (400 mg/day)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Nortriptyline (75 mg/day)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 109
Study: 2649118

Group type: EXPERIMENTAL
Intervention: Haloperidol 0.05 mg/kg/day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Haloperidol 0.025 mg/kg/day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Haloperidol (high dose)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 412041

Group type: EXPERIMENTAL
Intervention: Nitroprusside-Sodium (NPN)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intravenous Nitroglycerin (NTG)
Number of subjects: 12
Study: 6274503

Group type: EXPERIMENTAL
Intervention: Hyperthermia alone
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Hyperthermia combined with high-dose-rate external beam radiotherapy
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Interstitial thermoradiography
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Complications
Number of subjects: 43
Study: 30045133

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral (CB) intervention
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 29334416

Group type: EXPERIMENTAL
Intervention: Alcohol use (units per week)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cigarettes smoked per day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Smoking initiation
Number of subjects: 0
Study: 27029707

Group type: EXPERIMENTAL
Intervention: Tailored high-dose oral vitamin D supplementation (T)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Conventional vitamin D and calcium supplementation (C)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Tailored high-dose oral vitamin D supplementation (T) after switching from C
Number of subjects: 215
Study: 25212095

Group type: EXPERIMENTAL
Intervention: Caffeinated energy drink (3 mg caffeine/kg body mass)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo energy drink (0 mg caffeine/kg body mass)
Number of subjects: 90
Study: 22370839

Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus casei and Bifidobacterium breve), administered three times a day for an average treatment duration of 5.06±2.18 days
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo, administered three times a day for an average treatment duration of 5.49±3.17 days
Number of subjects: 70
Study: 21164556

Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AEx)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Resistance Exercise (REx)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sedentary Control
Number of subjects: 19
Study: 18269776

Group type: EXPERIMENTAL
Intervention: Pemetrexed 600 mg/m2 and epirubicin 75 mg/m2
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Pemetrexed 400‐600 mg/m2 and epirubicin 60‐90 mg/m2
Number of subjects: 56
Study: 16430107

Group type: EXPERIMENTAL
Intervention: Amlodipine + Perindopril
Number of subjects: 19257
Study: 12091596

Group type: EXPERIMENTAL
Intervention: Once-weekly subcutaneous epoetin beta treatment
Number of subjects: 173

Group type: COMPARATOR
Intervention: Three times weekly subcutaneous epoetin beta treatment
Number of subjects: 173
Study: 10191298

Group type: EXPERIMENTAL
Intervention: Post-heparin lipoprotein lipase (PH-LPL) activity in CAD patients
Number of subjects: 730

Group type: EXPERIMENTAL
Intervention: Lowest quartile of PH-LPL activity in CAD patients
Number of subjects: 730

Group type: EXPERIMENTAL
Intervention: Highest quartile of PH-LPL activity in CAD patients
Number of subjects: 730

Group type: EXPERIMENTAL
Intervention: Overall PH-LPL activity in CAD patients
Number of subjects: 730
Study: 7789550

Group type: EXPERIMENTAL
Intervention: Nal-Glu 100 micrograms/kg per day + T enanthate 50 mg IM weekly
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nal-Glu 200 micrograms/kg per day + T enanthate 50 mg IM weekly
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo + T enanthate 50 mg IM weekly
Number of subjects: 30
Study: 2112069

Group type: EXPERIMENTAL
Intervention: Fenfluramine (FF, 120 mg/day for 7 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (normal-weight women)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Basal conditions (before any drug administration)
Number of subjects: 20
Study: 435347

Group type: EXPERIMENTAL
Intervention: Hypotensive anaesthesia using halothane
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normotensive control group
Number of subjects: 30
Study: 30383246

Group type: EXPERIMENTAL
Intervention: RV‐A16 inoculum (n = 26)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (n = 10)
Number of subjects: 36
Study: 29040589

Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa followed by 300 IU highly purified HMG (hp-HMG)
Number of subjects: 152

Group type: COMPARATOR
Intervention: 300 IU daily recombinant FSH (rFSH)
Number of subjects: 152
Study: 25646321

Group type: EXPERIMENTAL
Intervention: Whole-grain wheat (WG) consumption for 4-8 weeks
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Whole-grain wheat (WG) consumption for 8 weeks
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Whole-grain wheat (WG) consumption
Number of subjects: 80

Group type: COMPARATOR
Intervention: Refined wheat (RW) consumption
Number of subjects: 80
Study: 23337405

Group type: EXPERIMENTAL
Intervention: Intracoronary shunt
Number of subjects: 40

Group type: COMPARATOR
Intervention: Snare
Number of subjects: 40
Study: 21880032

Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 489

Group type: COMPARATOR
Intervention: Itraconazole
Number of subjects: 489
Study: 19523725

Group type: EXPERIMENTAL
Intervention: Bread enriched with black currant press residue
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control bread without press residue
Number of subjects: 36
Study: 17378195

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with hyperbaric oxygenation
Number of subjects: 72

Group type: COMPARATOR
Intervention: Routine medicine and hyperbaric oxygenation
Number of subjects: 72
Study: 14975455

Group type: EXPERIMENTAL
Intervention: Sirolimus drug-eluting stent
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional stents
Number of subjects: 100
Study: 11323087

Group type: EXPERIMENTAL
Intervention: 600 mg alpha-lipoic acid per day
Number of subjects: 84

Group type: COMPARATOR
Intervention: No antioxidant treatment (Control)
Number of subjects: 84
Study: 9578794

Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 110

Group type: COMPARATOR
Intervention: Scintigraphy
Number of subjects: 110
Study: 7901636

Group type: EXPERIMENTAL
Intervention: Vitamin A (2.4 mg retinol) and placebo iron tablets
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Iron (60 mg elemental iron) and placebo vitamin A
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Vitamin A (2.4 mg retinol) and iron (60 mg elemental iron)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Both placebos
Number of subjects: 251
Study: 2832202

Group type: EXPERIMENTAL
Intervention: MACC polychemotherapy (methotrexate, doxorubicin HCl, cyclophosphamide and lomustine)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control subjects (before treatment)
Number of subjects: 8
Study: 31124428

Group type: EXPERIMENTAL
Intervention: CDI prevention collaborative intervention including onsite infection control and antimicrobial stewardship assessments, interactive learning sessions, and communication improvement initiative during June 2015‐June 2016.
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: CDI prevention collaborative intervention
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group of 27 ACHs in 3 San Francisco Bay Area counties
Number of subjects: 52
Study: 27813716

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) applied on the right side (diode laser 660 nm, 40 mW, 1 min, 2.4 J of total energy)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nonirradiated mini-implants (control group)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both groups (LLLT and control)
Number of subjects: 10
Study: 25946686

Group type: EXPERIMENTAL
Intervention: SYNTAX Score II (SSII) recommendation for CABG or PCI
Number of subjects: 202

Group type: COMPARATOR
Intervention: Heart Team (HT) decision to recommend CABG
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Preference for PCI irrespective of HT decision
Number of subjects: 202
Study: 24023757

Group type: EXPERIMENTAL
Intervention: 40 mg pravastatin for 3.2 years
Number of subjects: 5804

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 5804
Study: 21816077

Group type: EXPERIMENTAL
Intervention: Urine hepcidin concentrations at six and twenty-four hours after CPB in AKI-free patients (N = 91)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Urine hepcidin adjusted to urine creatinine at six hours after CPB
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Plasma hepcidin
Number of subjects: 100
Study: 19435164

Group type: EXPERIMENTAL
Intervention: After-school programs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison groups
Number of subjects: 0
Study: 16418021

Group type: EXPERIMENTAL
Intervention: 30 mL of bupivacaine (150 mg)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 30 mL of ropivacaine (150 mg)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Ropivacaine 150 mg, morphine 4 mg, and ketorolac 30 mg in normal saline (total volume 30 mL)
Number of subjects: 63
Study: 12925453

Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg pretreatment, 75 mg/d for 1 year)
Number of subjects: 2116

Group type: EXPERIMENTAL
Intervention: CYP3A4-MET statin (atorvastatin, lovastatin, simvastatin, cerivastatin) with clopidogrel
Number of subjects: 2116

Group type: EXPERIMENTAL
Intervention: Non-CYP3A4-MET statin (pravastatin, fluvastatin) with clopidogrel
Number of subjects: 2116

Group type: COMPARATOR
Intervention: Control (no pretreatment, 75 mg/d for 1 month)
Number of subjects: 2116

Group type: EXPERIMENTAL
Intervention: Concomitant therapy with statins
Number of subjects: 2116
Study: 10714533

Group type: EXPERIMENTAL
Intervention: Chiropractic spinal manipulative therapy (SMT) for 2 months (maximum of 16 treatments)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 127
Study: 8655877

Group type: EXPERIMENTAL
Intervention: Prednisone (20 mg) administered three times a day for 5 days
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 1421065

Group type: EXPERIMENTAL
Intervention: Amrinone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 30
Study: 6386095

Group type: EXPERIMENTAL
Intervention: Highly selective vagotomy (HSV)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Truncal vagotomy and pyloroplasty (TVP)
Number of subjects: 137
Study: 30251616

Group type: EXPERIMENTAL
Intervention: Individual placement and support (IPS) for 6 months in addition to treatment as usual (TAU)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) alone
Number of subjects: 146
Study: 29074815

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Standard Care + Hyperbaric Oxygen Therapy (SC+HBOT)
Number of subjects: 120
Study: 25965708

Group type: EXPERIMENTAL
Intervention: Ischemic postconditioning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deferred stent implantation in the infarct-related lesion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment of the culprit lesion only
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatment (primary angioplasty and complete revascularization)
Number of subjects: 0
Study: 24818336

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 200,000 IU ulinastatin in 100 mL of 0.9% saline given over one hour every 12 hours for 5 days
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo in 100 mL of 0.9% saline given over one hour every 12 hours for 5 days
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 200,000 IU ulinastatin
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study: 21769200

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg intravenously (i.v.)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combination of ondansetron 4 mg and dexamethasone 4 mg i.v.
Number of subjects: 100
Study: 19151299

Group type: EXPERIMENTAL
Intervention: Gabapentin 1200-1600 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Meloxicam 15 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of meloxicam and gabapentin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 0
Study: 17986361

Group type: EXPERIMENTAL
Intervention: Clinical pathway (appropriate use of practice guidelines, supplies of drugs and ancillary services, new organization and procedures, patient education)
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Clinical pathway
Number of subjects: 424

Group type: COMPARATOR
Intervention: Usual care (no intervention)
Number of subjects: 424
Study: 15146374

Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.4 mg daily for 12 weeks
Number of subjects: 69
Study: 11354394

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2% twice daily
Number of subjects: 106

Group type: COMPARATOR
Intervention: Dorzolamide 2% 3 times daily
Number of subjects: 106
Study: 7955995

Group type: EXPERIMENTAL
Intervention: CS-045 (400 mg daily)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 3599276

Group type: EXPERIMENTAL
Intervention: Superficial femoral-popliteal veins (SF-PVs)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Reversed saphenous veins (RSVs)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 120
Study: 29602433

Group type: EXPERIMENTAL
Intervention: Shock-Instructor (e-learning tool)
Number of subjects: 33
Study: 27166340

Group type: EXPERIMENTAL
Intervention: Generate group estimated their overall movement time then received knowledge of results of their actual movement time
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Choice group selected their perceived movement time from a list of three alternatives
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group did not self-report their perceived movement time and received knowledge of results of their actual movement time on every trial
Number of subjects: 36
Study: 25613105

Group type: EXPERIMENTAL
Intervention: Modified TAU + Therapeutic Education System (TES)
Number of subjects: 506

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 506
Study: 23582867

Group type: EXPERIMENTAL
Intervention: TF‐CBT (n = 24)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Wait-list control (n = 28)
Number of subjects: 52
Study: 20854930

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: tDCS
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Sertraline+tDCS
Number of subjects: 120
Study: 19070269

Group type: EXPERIMENTAL
Intervention: Subjective opioid withdrawal scale during detoxification (18 measurements)
Number of subjects: 200
Study: 17212098

Group type: EXPERIMENTAL
Intervention: Weekly hepatic arterial infusion (HAI) chemotherapy with 5-FU (1500 mg) for 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuous infusion group with identical total dosage of 5-FU
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weekly HAI chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HAI chemotherapy using a W spiral catheter
Number of subjects: 0
Study: 14616329

Group type: EXPERIMENTAL
Intervention: Nimodipine (30 microg x kg(‐1) h(‐1))
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo (0.9% saline solution)
Number of subjects: 43
Study: 10652688

Group type: EXPERIMENTAL
Intervention: Individual outreach
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Health education classes
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Ongoing follow-up counseling
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Screening alone
Number of subjects: 2000
Study: 9332680

Group type: EXPERIMENTAL
Intervention: Zorubicin 325 mg/m2, day 1 (Group A)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Zorubicin 250 mg/m2, day 1 and cisplatin 30 mg/m2, days 2-5 (Group B)
Number of subjects: 80
Study: 8877187

Group type: EXPERIMENTAL
Intervention: Topical beclomethasone (100 micrograms spray to each nasal cavity twice daily for 3 weeks)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (saline treatment for 3 weeks)
Number of subjects: 8
Study: 3772840

Group type: EXPERIMENTAL
Intervention: TM plus home exercise training
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: TM plus medically supervised gym training
Number of subjects: 210

Group type: COMPARATOR
Intervention: TM without formal exercise program
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control group (seen only at six months post MI)
Number of subjects: 210
Study: 29763339

Group type: EXPERIMENTAL
Intervention: V‐shaped distal triceps tendon repair technique
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Knotless suture‐bridge repair technique
Number of subjects: 24

Group type: COMPARATOR
Intervention: Transosseous cruciate repair technique
Number of subjects: 24
Study: 26004120

Group type: EXPERIMENTAL
Intervention: Custom-made foot orthoses
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham foot orthoses
Number of subjects: 24
Study: 23567372

Group type: EXPERIMENTAL
Intervention: Hip fracture surgery
Number of subjects: 142